ACRS

Aclaris Therapeutics, Inc.

1.24 USD
+0.09 (+7.83%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aclaris Therapeutics, Inc. stock is up 11.71% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 June’s closed higher than May.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.